Business, energy, technology, markets and global industry news from Business News Today

United States Food and Drug Administration

PharmaDeviceNews United States Food and Drug Administration
A clinical research setting illustrates Arrowhead Pharmaceuticals’ Phase 3 YOSEMITE trial evaluating zodasiran for homozygous familial hypercholesterolemia following completion of global patient enrollment. Representative image.
Pharma & Biotech

Arrowhead has enrolled 70 patients in a rare cholesterol trial, but can zodasiran clear the Phase 3 bar?

Arrowhead completes Phase 3 YOSEMITE enrollment as zodasiran faces a crucial test of LDL cholesterol lowering in patients with severe HoFH.

Read More
Thermo Fisher Scientific’s ADLM 2026 showcase highlights integrated diagnostic testing, laboratory automation, quality controls and digital workflows designed to support modern clinical laboratories. Representative image.
Medical Devices & Diagnostics

Thermo Fisher Scientific expands specialty diagnostics strategy with EXENT and EliA CTD 13 Screen

Thermo Fisher’s ADLM 2026 showcase links new diagnostics, lab quality tools and workflow scale, while active device corrections test execution.

Read More
IceCure Medical’s ChoICE post-market study is evaluating the ProSense cryoablation system as a minimally invasive treatment option for eligible older patients with low-risk, early-stage breast cancer. Representative image.
Medical Devices & Diagnostics

What will IceCure Medical’s ChoICE study reveal about ProSense breast cancer cryoablation?

IceCure Medical launches the ChoICE post-market study at West Cancer Center, testing ProSense adoption and five-year outcomes in breast cancer.

Read More
Representative image: A clinician applies a microneedle skin patch as Medicus Pharma $MDCX advances its SkinJect treatment into an FDA-cleared Phase 2b study for basal cell carcinomas in Gorlin syndrome.
Pharma & Biotech

FDA clears Medicus Pharma SkinJect registrational study in Gorlin syndrome

FDA clears Medicus Pharma’s Phase 2b SkinJect study in Gorlin syndrome with biopsy-confirmed endpoints and two-year follow-up.

Read More
AbelZeta’s FDA-cleared registrational Phase II trial will evaluate the investigational dual-target CAR-T therapy C-CAR168 in patients with refractory lupus nephritis. Representative image.
Pharma & Biotech

Can AbelZeta turn a tiny lupus dataset into a registrational CAR-T breakthrough?

AbelZeta's FDA-cleared Phase II C-CAR168 trial tests whether dual-target CAR-T can deliver durable renal responses in refractory lupus nephritis.

Read More
Laboratory research illustrates Decoy Therapeutics’ investigation of D-MAV antiviral candidates after reporting early in vitro activity against Ebola Zaire virus. Representative image.
Pharma & Biotech

A coronavirus antiviral candidate hit Ebola in the lab. How far can Decoy Therapeutics take it?

Decoy Therapeutics reports early Ebola Zaire activity, but potency data, animal validation and funding will determine the D-MAV program.

Read More
Representative image: Laboratory blood samples illustrate Freenome’s SimpleScreen CRC FDA approval as Abbott Laboratories $ABT prepares to launch the blood-based colorectal cancer screening test in the United States.
Pharma & Biotech

FDA approves Freenome SimpleScreen CRC blood test as Abbott prepares US launch

FDA approves Freenome’s SimpleScreen CRC blood test as Abbott plans a fall launch. See its benefits, limits and colonoscopy requirement.

Read More
An ophthalmic surgeon performs a glaucoma procedure as Glaukos Corporation advances the PRESERFLO MicroShunt through its U.S. pivotal study following completion of patient enrollment. Representative image.
Medical Devices & Diagnostics

Glaukos has enrolled the PRESERFLO pivotal study, but the decisive U.S. evidence is still ahead

Glaukos completes PRESERFLO pivotal enrollment, shifting focus to 12-month data, FDA clearance and advanced glaucoma adoption.

Read More
Yarrow Bioscience’s merger with VYNE Therapeutics and the start of Phase 2 dosing for investigational YB-101 place Graves’ disease and thyroid eye disease research at the centre of the newly listed biotechnology company’s strategy. Representative image.
Pharma & Biotech

Yarrow Bioscience closes VYNE Therapeutics merger as YB-101 enters Phase 2 trial in Graves’ disease

Yarrow Bioscience starts Phase 2 dosing of YB-101 after its VYNE merger, testing a targeted approach to Graves’ disease and thyroid eye disease.

Read More
Redox and Lapsi Health are integrating the Keikku clinical AI platform with electronic health record workflows to support connected documentation, clinical data access and digital auscultation. Representative image.
Medical Devices & Diagnostics

Can Redox fix the integration bottleneck standing between Keikku and hospital-scale AI adoption?

Redox and Lapsi Health are linking Keikku with EHR workflows, but adoption will depend on validation, governance and health-system execution.

Read More